TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The investigational Lyme disease vaccine LB6V did not meet its prespecified Phase III success threshold in the evaluable population, despite an estimated 73.2% efficacy. A modified intent-to-treat analysis produced a 74.8% estimate that narrowly cleared the threshold. Protection appeared to decline in the third season, and the vaccine is not approved.
An investigational Lyme disease vaccine showed an estimated 73.2% efficacy in a Phase III trial but missed its prespecified statistical success threshold in the evaluable population, according to results presented October 27 at the IDWeek annual meeting. A modified intent-to-treat analysis narrowly met the threshold, leaving the trial’s primary result short of its predefined benchmark while suggesting possible protection against the tick-borne disease.
Among participants aged 5 and older in the evaluable population, four people who received four doses of LB6V developed Lyme disease, compared with 15 who received placebo. The resulting vaccine efficacy estimate was 73.2%, with a 95% confidence interval of 15.8% to 93.5%. The trial required the lower end of that interval to be greater than 20%, so this analysis did not meet the preset criterion.
In a modified intent-to-treat analysis, the estimated efficacy was 74.8%, with a 95% confidence interval of 21.7% to 93.9%—just above the same lower-bound threshold. Paul Auwaerter, MD, of Johns Hopkins University School of Medicine, presented the findings. The two analyses should be distinguished: one missed the statistical benchmark, while the other cleared it narrowly.
The VALOR trial enrolled about 9,400 people ages 5 and older considered at increased risk because of their work, home environment or leisure activities. Participants in the United States, Canada and five European countries received vaccine or placebo at baseline, two months, about five to nine months, and about 18 months. The primary efficacy period began 28 days after dose four and ran through the end of the Lyme disease season.
What the Trial Result Means
The result is a mixed signal for a vaccine candidate in an area with no currently available Lyme disease vaccine. The evaluable analysis did not satisfy the trial’s preset criterion, so the reported 73.2% estimate alone does not establish that the candidate met its primary statistical target. The modified analysis did clear that benchmark, but only narrowly. How regulators and the sponsor interpret the difference between the analyses will matter to any next steps.
Durability is another concern raised by the results. The reported efficacy estimate fell from 73.2% in the second season to 18.6% in the third; the third-season confidence interval was very wide, from -220.0% to 80.4%. The antibody measure reported in the trial also declined over that period. These findings point to uncertainty about how long protection might last and whether a booster schedule would be needed; they do not establish what schedule would work.
The public health stakes are substantial. The source report says more than 80,000 U.S. Lyme disease cases are reported to the CDC each year and estimates 476,000 people are treated annually. Lyme disease can cause fever, headache, fatigue and a characteristic rash, and untreated infection can spread to joints, the heart and nervous system. Those figures help explain the interest in prevention, but they do not change the trial’s statistical result.
Products Worth Considering
Amazon Kindle Paperwhite (12th Generation, 2024), 16 GB, 7-inch Display, Jade
Samsung 27-inch Odyssey OLED G6 QD-OLED QHD Gaming Monitor
DJI Osmo Pocket 3 Filter Bundle – Vlogging Camera with 1 CMOS Sensor and 4K/120fps
As an affiliate, we earn on qualifying purchases.
How LB6V Was Tested
LB6V, previously known as VLA15, is an adjuvanted protein subunit vaccine designed to target six serotypes across four Borrelia species common in Europe and North America. The proposed mechanism is that vaccinated people pass antibodies to ticks during a bite; the antibodies then inhibit the bacteria in the tick and prevent transmission to a person. Earlier Phase II studies generated immune responses and appeared to show an acceptable safety profile, according to the source report.
The Phase III study followed participants across three Lyme disease seasons from 2022 to 2025. The median participant age was 47; 52% were female, 95.8% were white and 97% had at least two Lyme disease risk factors. These details describe the enrolled group and should be considered when judging how closely the results apply to people outside the trial.
The United States previously had a Lyme disease vaccine: the FDA approved LYMErix in 1998, but its manufacturer withdrew it from the market in 2002 amid concerns about side effects and declining sales, as described in the report. LB6V would be a new candidate, not a return of that product, and the trial results do not mean it is available to the public.
“Overall, I do think this vaccine has the potential to lower the Lyme disease burden.”
— Paul Auwaerter, MD, of Johns Hopkins University School of Medicine
Open Questions on Protection
The reported results do not establish whether LB6V will advance toward regulatory review or what evidence may be required next. The source report does not provide a sponsor decision, a regulatory filing timeline or a full account of how the modified intent-to-treat analysis was defined relative to the evaluable population. The difference between the analyses therefore remains important to interpreting the trial outcome.
How well the vaccine protects over time is also unsettled. The third-season efficacy estimate was 18.6%, but its confidence interval was extremely broad and included values on either side of no effect. The fall in antibody levels is consistent with waning immune response, but the results provided do not settle how those levels translate into protection for individuals or establish the timing or value of a booster.
Safety findings need to be read alongside those limitations. Adverse events were reported in 58.8% of vaccine recipients and 52.6% of placebo recipients. Fatigue, headache, muscle and joint pain, and injection-site pain, redness and swelling were more common among vaccine recipients. Treatment-related events that prompted withdrawal occurred in 0.3% of vaccine recipients and 0.1% of placebo recipients. Newly diagnosed chronic medical conditions were reported at similar rates, 9.6% and 9.5%, respectively. These figures do not by themselves resolve the overall benefit-risk assessment.
Next Steps for the Vaccine
The next developments will depend on the trial sponsor’s interpretation of the data and any discussions with regulators. The source report does not state whether the company plans another study, a regulatory submission or a revised dosing approach. Until those plans are announced, the results should be treated as trial findings rather than evidence that a vaccine is ready for use.
Further analysis may clarify the role of antibody levels as a marker of protection. Auwaerter said the relationship between antibody titers and Lyme disease risk may provide a basis for future immunobridging studies, which use immune-response data to help assess protection. The study results also raise the possibility of an annual booster before Lyme season, but that remains a suggestion, not a validated schedule.
For now, LB6V remains investigational. Readers should watch for a sponsor update or peer-reviewed publication with fuller trial methods and results, including details on the statistical analyses and plans for evaluating protection over additional seasons.
Key Questions
Did LB6V meet the Phase III trial’s success threshold?
Not in the evaluable population analysis. Its 73.2% efficacy estimate had a 95% confidence interval with a lower bound of 15.8%, below the required level of greater than 20%. A modified intent-to-treat analysis estimated 74.8% efficacy, with a lower bound of 21.7%, and narrowly met that criterion.
How many Lyme disease cases occurred in the main analysis?
Among participants in the evaluable population aged 5 and older, four vaccine recipients and 15 placebo recipients developed Lyme disease, according to the trial results presented at IDWeek.
Is the Lyme disease vaccine available now?
No. LB6V is described as an investigational vaccine candidate. The source report does not say that it has been approved or made available to the public.
Did the vaccine’s estimated protection last across the study?
The reported efficacy estimate was 73.2% in the second season and 18.6% in the third. The third-season confidence interval was very wide, so the estimate is uncertain; the findings also do not establish a booster schedule.
What side effects were reported more often with LB6V?
Fatigue, headache, muscle pain, joint pain, and injection-site pain, redness and swelling were more likely among vaccine recipients than placebo recipients. Adverse events overall occurred in 58.8% of vaccine recipients and 52.6% of placebo recipients.
Source: rss
